Logo image of CING

CINGULATE INC (CING) Stock Fundamental Analysis

NASDAQ:CING - Nasdaq - US17248W3034 - Common Stock - Currency: USD

4.05  -0.05 (-1.22%)

After market: 4.06 +0.01 (+0.25%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CING. CING was compared to 195 industry peers in the Pharmaceuticals industry. CING has a bad profitability rating. Also its financial health evaluation is rather negative. CING is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CING has reported negative net income.
In the past year CING has reported a negative cash flow from operations.
In the past 5 years CING always reported negative net income.
In the past 5 years CING always reported negative operating cash flow.
CING Yearly Net Income VS EBIT VS OCF VS FCFCING Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -131.33%, CING is doing worse than 81.03% of the companies in the same industry.
CING has a Return On Equity of -276.12%. This is in the lower half of the industry: CING underperforms 74.36% of its industry peers.
Industry RankSector Rank
ROA -131.33%
ROE -276.12%
ROIC N/A
ROA(3y)-311.2%
ROA(5y)-229.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CING Yearly ROA, ROE, ROICCING Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CING so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CING Yearly Profit, Operating, Gross MarginsCING Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, CING has more shares outstanding
CING has less shares outstanding than it did 5 years ago.
The debt/assets ratio for CING has been reduced compared to a year ago.
CING Yearly Shares OutstandingCING Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
CING Yearly Total Debt VS Total AssetsCING Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -14.90, we must say that CING is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -14.90, CING is doing worse than 76.92% of the companies in the same industry.
A Debt/Equity ratio of 0.85 indicates that CING is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.85, CING is not doing good in the industry: 69.74% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Altman-Z -14.9
ROIC/WACCN/A
WACCN/A
CING Yearly LT Debt VS Equity VS FCFCING Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 1.87 indicates that CING should not have too much problems paying its short term obligations.
CING's Current ratio of 1.87 is on the low side compared to the rest of the industry. CING is outperformed by 62.56% of its industry peers.
A Quick Ratio of 1.87 indicates that CING should not have too much problems paying its short term obligations.
The Quick ratio of CING (1.87) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.87
Quick Ratio 1.87
CING Yearly Current Assets VS Current LiabilitesCING Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 84.15% over the past year.
EPS 1Y (TTM)84.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CING will show a very strong growth in Earnings Per Share. The EPS will grow by 23.31% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y73.21%
EPS Next 2Y33.57%
EPS Next 3Y25.24%
EPS Next 5Y23.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CING Yearly Revenue VS EstimatesCING Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
CING Yearly EPS VS EstimatesCING Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CING reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CING. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CING Price Earnings VS Forward Price EarningsCING Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CING Per share dataCING EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

CING's earnings are expected to grow with 25.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.57%
EPS Next 3Y25.24%

More info and screens

0

5. Dividend

5.1 Amount

CING does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CINGULATE INC

NASDAQ:CING (6/27/2025, 8:00:00 PM)

After market: 4.06 +0.01 (+0.25%)

4.05

-0.05 (-1.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)N/A N/A
Inst Owners3.22%
Inst Owner Change50.59%
Ins Owners0.01%
Ins Owner Change0%
Market Cap17.21M
Analysts82
Price Target29.38 (625.43%)
Short Float %7.6%
Short Ratio1.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.11%
PT rev (3m)-18.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)38.47%
EPS NY rev (1m)-2.49%
EPS NY rev (3m)31.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.9
P/tB 2.9
EV/EBITDA N/A
EPS(TTM)-10.21
EYN/A
EPS(NY)-2.57
Fwd EYN/A
FCF(TTM)-3.4
FCFYN/A
OCF(TTM)-3.37
OCFYN/A
SpS0
BVpS1.4
TBVpS1.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -131.33%
ROE -276.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-311.2%
ROA(5y)-229.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.87
Quick Ratio 1.87
Altman-Z -14.9
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)36.45%
Cap/Depr(5y)56.62%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.56%
EPS Next Y73.21%
EPS Next 2Y33.57%
EPS Next 3Y25.24%
EPS Next 5Y23.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.25%
OCF growth 3YN/A
OCF growth 5YN/A